Purdue Ventures invests in antibody-based cancer therapeutics company

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy effects against malignant tumors.

March 29, 2024

Vol.50 No.13

Clinical Roundup

Discovery at Purdue points to new approach to treating liver cancer

A study of the relationship between the enzyme DDX5, liver cancer and sorafenib, published in the Nature journal Cell Death & Disease points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.

December 08, 2023

Vol.49 No.45

In Brief

Purdue names new pediatric cancer research center for the late Tyler Trent

Purdue University renamed its pediatric cancer research center the Tyler Trent Pediatric Cancer Research Center within the Purdue Institute for Cancer Research.

October 20, 2023

Vol.49 No.39

In Brief

Andrew Mesecar named director of Purdue Institute for Cancer Research

Andrew Mesecar, Distinguished Professor of Biochemistry and the Walther Professor in Cancer Structural Biology, was named assistant vice president for research and director of the Purdue Institute for Cancer Research after serving, since Aug. 2022, as interim director. Mesecar was chosen for the position after a nationwide search.

October 13, 2023

Vol.49 No.38

Clinical Roundup

Purdue’s Philip Low receives $1.3M to develop malaria drug trials using imatinib in Southeast Asia and Africa

Open Philanthropy has awarded $1.38 million to Philip Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science, to validate a drug therapy using imatinib to treat malaria.

September 22, 2023

Vol.49 No.35

Clinical Roundup

Purdue researchers develop cancer immunotherapy treatment using PTPN22 enzyme

Researchers in Purdue University’s College of Pharmacy are further developing a potential immunotherapy treatment for cancer, one focused on the mutation of the PTPN22 enzyme.

January 14, 2022

Vol.48 No.02

Purdue Ventures invests in antibody-based cancer therapeutics company

YOU MAY BE INTERESTED IN

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

Discovery at Purdue points to new approach to treating liver cancer

Purdue names new pediatric cancer research center for the late Tyler Trent

Andrew Mesecar named director of Purdue Institute for Cancer Research

Purdue’s Philip Low receives $1.3M to develop malaria drug trials using imatinib in Southeast Asia and Africa

Purdue researchers develop cancer immunotherapy treatment using PTPN22 enzyme

Renew today!

Subscriber content

Never miss an issue!

Login